Bayer Wins First-in-Class Stroke Approval as Kepler and Berenberg Diverge on the Upside
Published on 11/19/2026 at 21:30 | Editorial boerse-global.deBayer has secured the world's first regulatory green light for a factor XIa inhibitor, with the US Food and Drug Administration clearing asundexian under the brand name Sunharbo in early November. The approval covers use of the drug to lower the risk of further strokes — a milestone the German group describes as unprecedented for the entire drug class.
The news lands alongside a sharp split in how sell-side analysts are pricing Bayer's prospects. Kepler Cheuvreux raised its target on the stock to EUR 69 from EUR 58 and recommends buying the shares. Berenberg, by contrast, lifted its own target to EUR 62.00 from EUR 53.50 but stuck with a Hold rating.
Berenberg's move came on Tuesday, and analyst Sebastian Bray anchored the increase partly on what he views as a strong year for Bayer so far. He also flagged a possible later stock-market listing of Monsanto, with proceeds from such a move potentially channelled into pharmaceutical development.
Should investors sell immediately? Or is it worth buying Bayer?
Quarterly Beat Underpins Raised Outlook
The analyst revisions follow third-quarter 2026 results published on 3 November. Bayer reported group revenue of EUR 10.1 billion and EBITDA before special items of EUR 1.62 billion, with adjusted earnings per share of EUR 0.31.
Alongside the figures, the company lifted its guidance for the EBITDA margin of its pharmaceutical division. It also held out the prospect of higher group EBITDA before special items and a stronger free cash flow figure than previously indicated.
Kepler's more bullish stance did not shield the shares from a broader market retreat. Bayer slipped 2.5% in a weak session, dragged down with other pharmaceutical names. European bourses extended their downward trend in the wake of softer US markets, according to dpa-AFX, with Novartis and Nestlé weighing on the Swiss market. Germany's DAX, after attempting to stabilise in the morning, closed 1.1% lower — its fifth consecutive trading day of losses.
The stock has since edged up 0.4%, though it still trades 3.2% below its 52-week high.
Ad
Bayer Stock: New Analysis - 19 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
